{"title":"What is the value of the chest radiograph as a simple method of diagnosing emphysema and assessing its severity?","authors":"","doi":"10.1016/j.rmedu.2008.02.002","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.02.002","url":null,"abstract":"<div><p>The objectives of our study were to reappraise chest radiography in the diagnosis of emphysema using computed tomography (CT) as the reference standard, and to establish whether chest radiography is useful in phenotyping chronic obstructive pulmonary disease (COPD). We studied 154 patients who had postero-anterior and lateral chest radiographs and CT for diagnostic purposes. CT were scored for emphysema using the picture-grading method. Chest radiographs were examined independently by five raters using four criteria for emphysema validated against lung pathology. Next, we applied these criteria to assess the prevalence of emphysema in 458 COPD patients. Patients with and without evidence of emphysema were compared as regards age, gender, pack-years of smoking, BMI, FEV1, DLCO, and health status. Chest radiography yielded 90% sensitivity and 98% specificity for emphysema. Of 458 COPD patients, 245 had radiologic evidence of emphysema. Emphysemic patients had significantly lower BMI, FEV1, and DLCO, greater restriction of physical activity, and worse quality of life than non emphysemic ones. There was no difference across the two groups as to age, gender, or pack-years of smoking. Chest radiography is a simple means for diagnosing moderate to severe emphysema. It is useful in phenotyping COPD, and may aid physicians in their choice of treatment.<br></p><p>Reproduced with permission from European Respiratory Society Journals Ltd.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 2","pages":"Pages 71-72"},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Atherosclerosis, COPD and chronic inflammation","authors":"Magnus Bäck","doi":"10.1016/j.rmedu.2008.01.007","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.01.007","url":null,"abstract":"<div><p><span><span><span>The prevalence of ischemic heart disease is approximately twofold higher in </span>chronic obstructive pulmonary disease (COPD) cohorts compared to the general population. Likewise, cardiac patients with COPD have a reduced short- and long-term survival. This co-morbidity of COPD with atherosclerotic vessel disease is associated with common risk factors, such as smoking. However, </span>atherosclerosis<span>, in addition, shares many of the inflammatory mechanisms with those found in COPD. Atherosclerotsic lesions, as well as the COPD lung, are sites of local inflammation. Furthermore, a systemic inflammatory response, measured as increased CRP<span>, has been reported in both patient populations. There are a number of inflammatory mediators<span> produced in both the vessel wall and in the lungs, which potentially induce common pathological processes. For example, leukotriene B</span></span></span></span><sub>4</sub><span><span><span>, which induces chemotaxis of neutrophils<span>, monocytes, T-lymphocytes and </span></span>smooth muscle cells<span>, has been suggested as a therapeutic target in both diseases. Furthermore, activation of smooth muscle cells may lead to a narrowing of the lumen in both airways and vessels. Finally, proteolytic activities of </span></span>matrix metalloproteinases<span><span><span> may be involved both in emphysema formation and in atherosclerotic plaque rupture, leading to myocardial infarction and stroke. Taken together, the associated co-morbidity of COPD with atherosclerosis and their potential common pathophysiological mechanisms support a notion of these, and other </span>inflammatory diseases, as manifestations of </span>chronic inflammation.</span></span></p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 2","pages":"Pages 60-65"},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.01.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Change in patient health status following an acute COPD exacerbation","authors":"","doi":"10.1016/j.rmedu.2008.01.004","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.01.004","url":null,"abstract":"<div><p>The current study aimed to assess the impact on patient health status during an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). A total of 421 COPD patients were enrolled in a multicentre, single-arm study with a 6-month observational follow-up period. Patients received two inhalations of Symbicort 200 Turbuhaler(R) twice a day. Patients were assessed before the run-in period, at baseline and at 1, 3 and 6 months. Patients were instructed to report a change in respiratory symptoms lasting >24<!--> <!-->h. This defined an AECOPD. In addition to the initial call, the St George's Respiratory Questionnaire (SGRQ), COPD Control Questionnaire (CCQ), Medical Research Council (MRC) dyspnoea scale and activities of daily living (ADL) were completed at 5–7 and 12–14 days. A group of 176 patients reported at least one AECOPD. Exacerbations were associated with statistically significant mean changes (worsening) in the SGRQ activity and impact domains at onset (mean+/−sd 12.1+/−18.1 and 14.0+/−15.2), during the first (9.8+/−19.0 and 9.4+/−16.6) and second weeks (3.1+/−15.5 and 3.3+/−14.7). Clinically significant deterioration in SGRQ impact scores was shown in 71% of patients following early identification, with 55 and 37% during the first and second weeks of an AECOPD, respectively. Acute exacerbation severely impacts on health status. The current study provides valuable information on the change in health status during an acute exacerbation of chronic obstructive pulmonary disease that can be utilised for future trials that evaluate therapeutic intervention.<br></p><p>Reproduced with permission from European Respiratory Society Journals Ltd.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 2","pages":"Page 84"},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137347541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Do PaO2 and adverse social circumstances affect outpatient treatment of COPD exacerbations?","authors":"","doi":"10.1016/j.rmedu.2008.01.006","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.01.006","url":null,"abstract":"<div><p>The current British Thoracic Society guidelines on COPD recommend that patients with COPD exacerbations should be admitted to hospital if they either have partial pressure of arterial oxygen of <7.0 kilopascals (kPa) or if they are living alone. This study was carried out to see if either of these factors have any effect on the outcome in patients presenting with COPD exacerbation in the setting of well established COPD services. This study was to see if patients with PaO(2) <7.0<!--> <!-->kPa or those living alone were readmitted more frequently or had higher mortality than other patients discharged through the same scheme. A retrospective analysis was carried out on 1078 patients with acute exacerbation of COPD who were discharged home through Wigan “hospital at home” scheme in the period between November 1999 and February 2004 prior to the introduction of the new guidelines. This study found that there was no statistically significant difference in the rates of readmissions in patients with low PaO(2) or those living in adverse social circumstances compared to other groups of patients. The number of patients dying in this period was too small to analyse with adequate power. This study indicates that such patients can be safely managed at home in the context of well established COPD services.<br></p><p>Reproduced with permission from Sage Publications Ltd.</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 2","pages":"Page 87"},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.01.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137347542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Can COPD patients benefit from treatment with infliximab?","authors":"","doi":"10.1016/j.rmedu.2008.02.017","DOIUrl":"https://doi.org/10.1016/j.rmedu.2008.02.017","url":null,"abstract":"<div><h3>Rationale</h3><p>Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-alpha is overexpressed and has been suggested to play a pathogenic role.</p></div><div><h3>Objectives</h3><p>To determine if infliximab, an anti-TNF-alpha antibody, results in clinical benefit and has an acceptable safety profile in patients with moderate to severe COPD. METHODS: In a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study, subjects with moderate to severe COPD received infliximab (3<!--> <!-->mg/kg [<em>n</em>=78] or 5<!--> <!-->mg/kg [<em>n</em>=79]) or placebo (<em>n</em>=77) at Weeks 0, 2, 6, 12, 18, and 24. Efficacy, health status, and safety were assessed through Week 44.</p></div><div><h3>Measurements and main results</h3><p>Infliximab was generally well tolerated, but showed no treatment benefit as measured by the primary endpoint, Chronic Respiratory Questionnaire total score. Similarly, there was no change in secondary measures, including prebronchodilator FEV(1), 6-min walk distance, SF-36 physical score, transition dyspnea index, or moderate-to-severe COPD exacerbations. Post hoc analysis revealed that subjects who were younger or cachectic showed improvement in the 6-min walk distance. Malignancies were diagnosed during the study in 9 of 157 infliximab-treated subjects versus 1 of 77 placebo-treated subjects. No opportunistic infections were observed, and there were no differences in the occurrence of antibiotic-requiring infections, although the incidence of pneumonia was higher in infliximab-treated subjects. No infection-related mortality was observed. Higher proportions of infliximab-treated subjects discontinued the study agent due to adverse events (20-27%) than did placebo-treated subjects (9%).</p></div><div><h3>Conclusions</h3><p>Subjects with moderate to severe COPD did not benefit from treatment with infliximab. Although not statistically significant, more cases of cancer and pneumonia were observed in the infliximab-treated subjects. The impact of infliximab on malignancy risk in patients with COPD needs to be further elucidated.</p><p>Reproduced with permission from the American Thoracic Society</p></div>","PeriodicalId":101083,"journal":{"name":"Respiratory Medicine: COPD Update","volume":"4 2","pages":"Page 80"},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedu.2008.02.017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
